Overview of Erevit

Property	Description
Active ingredient	Sildenafil (as Sildenafil citrate)
Form	Oral tablet
Pharmacological class	Phosphodiesterase type 5 (PDE5) Inhibitor
Origin	Synthetic organic compound
General purpose	To modulate and improve blood flow

Erevit is a prescription-only medication containing the active ingredient Sildenafil, a synthetic organic compound that is the internationally recognized substance in the formulation. This component has established effects on vascular tone. Erevit is classified pharmacologically as a highly selective Phosphodiesterase type 5 (PDE5) inhibitor and is supplied primarily as an oral formulation for oral administration. The drug entity is defined by its ability to modulate a key enzymatic pathway that influences smooth muscle tone in specific vascular beds.

What Type of Medicine is Erevit (Sildenafil)?

Erevit is definitively categorized as a highly selective Phosphodiesterase type 5 (PDE5) inhibitor, a well-established pharmacological class of agents. This classification signifies its unique mechanism: it targets the PDE5 enzyme, preventing the hydrolysis of cyclic Guanosine Monophosphate (cGMP). Sildenafil’s selective inhibitory action on PDE5 results in increased cGMP levels in certain tissues. This means the medicine works by preserving a natural chemical messenger that causes muscle relaxation.

The Composition and Form of Erevit

The active ingredient in Erevit is Sildenafil, typically used in the form of its salt, Sildenafil citrate. Erevit is a single active ingredient product, presented as a tablet for oral administration, utilizing a solid oral tablet base composed of inert excipients for precise delivery. This defined composition and reliable oral formulation are crucial for achieving the necessary systemic bioavailability of Sildenafil to induce its therapeutic effects throughout the body. The general purpose of Erevit is clinically recognized for addressing conditions where enhanced blood flow is required.

What is the General Purpose of a PDE5 Inhibitor?

The general purpose of a PDE5 inhibitor like Sildenafil is rooted in its ability to enhance the action of nitric oxide (NO) by preventing the rapid breakdown of cGMP. This fundamental physiological action leads directly to smooth muscle relaxation and resultant vasodilation in the targeted tissues. Sildenafil selectively inhibits PDE5, resulting in peripheral and pulmonary vasodilation. The core benefit is the ability to widen blood vessels to improve circulation. The primary effect of this mechanism is to improve or modulate blood flow in systems where such enhancement is therapeutically desirable.

Regulatory References

Sildenafil: MedlinePlus Drug Information

What side effects are possible with Erevit?

Possible side effects and safety information

The safety profile for Erevit (Sildenafil) is structured by government regulatory bodies using standardized classifications of adverse reactions based on frequency of occurrence. The officially documented adverse effects involve several body systems, primarily reflecting the drug's vasodilatory action.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to their observed frequency in clinical studies and post-marketing surveillance:

Classification	Examples of Officially Documented Effects
Very Common (ge 1/10)	Headache, Flushing
Common (ge 1/100 to < 1/10)	Dizziness, Dyspepsia, Visual disturbances, Nasal congestion, Nausea
Uncommon (ge 1/1,000 to < 1/100)	Vomiting, Hypotension, Tachycardia, Myalgia, Rash
Rare (ge 1/10,000 to < 1/1,000)	Non-arteritic anterior ischemic optic neuropathy (NAION), Priapism, Sudden hearing loss

Documented Safety Considerations

The official labeling notes specific, rare, but clinically important adverse reactions. These include Priapism (an erection lasting longer than four hours), sudden decrease or loss of hearing, and Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision. Post-marketing reports also include serious cardiovascular events such as stroke and myocardial infarction.

Regulatory documents specify safety notes for certain patient populations. Reduced drug clearance is officially documented in older adults (aged 65 years or more) and in patients with severe renal or hepatic impairment. Furthermore, an absolute safety restriction prohibits the concomitant use of Erevit with any form of organic nitrate due to the risk of severe, life-threatening hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Erevit (Sildenafil) is officially documented as resulting in an exaggeration of the drug’s known pharmacological effects, primarily due to heightened vasodilation. This typically presents as an increased frequency and severity of common adverse reactions.

Overdose Scope (Regulatory Classification)	Official Statement Summary
Documented Manifestations	Symptoms noted with excessive exposure include an increased incidence of headache, flushing, dizziness, dyspepsia, and temporary visual colour distortions.
Severe Outcomes	Serious labeled risks include severe hypotension, myocardial infarction, sudden cardiac death, and the potential for priapism (an erection lasting 4 hours). Sudden loss of vision or hearing are also documented as events requiring urgent action.
Population Notes	Regulatory documents indicate that drug clearance is reduced in patients with severe renal impairment and hepatic impairment, a factor relevant for overdose management.

Immediate Emergency Action Required

Regulators mandate that individuals must seek immediate medical assistance for any erection that persists for longer than four hours to prevent permanent tissue damage. Prompt medical attention must also be sought immediately in the event of sudden visual defects or a sudden decrease or loss of hearing. Management is restricted to symptomatic and supportive treatment, as official documents state that no specific antidote is known. The official profile requires close blood pressure monitoring during emergency management.

Therapeutic Uses of Erevit

What Erevit treats: Main Uses and Benefits

The core therapeutic purpose of Erevit (Sildenafil) is to offer supportive therapeutic benefit for conditions related to impaired blood flow and vascular tone. This medication is commonly used to help with two main categories of conditions: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Support for Impaired Erectile Function

Erevit is relevant for managing symptoms of ED in adult males, addressing the functional problem of the inability to achieve or sustain an erection firm enough for satisfactory sexual activity. This use may assist with maintaining functional stability and contributes to improved comfort in situations where patients experience functional strain.

“The medication is generally applied in scenarios where additional symptomatic support is required to support the body’s responsiveness.”

Management of Pulmonary Arterial Hypertension (PAH) Symptoms

Erevit is also applied in chronic management contexts for PAH, a condition characterized by constricted blood vessels in the lungs. It is relevant for easing symptoms that interfere with daily functioning, such as reduced exercise capacity and fatigue. By helping to moderate the symptomatic effects of pressure in the pulmonary arteries, this provides support that contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relief for Functional Strain
Erevit is used for managing symptoms that create noticeable physiological strain in two distinct systems: the male reproductive system (in situations involving certain distressing symptoms) and the cardiopulmonary system (in conditions marked by increased physiological stress). It helps in both contexts by assisting with maintaining functional stability.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory status for Erevit defines strict criteria for patient eligibility and exclusion, based on governmental documentation such as the FDA Prescribing Information.

Contraindications and Exclusion Criteria

Erevit is contraindicated and must not be used in females who are pregnant due to the risk of fetal harm (Embryo-Fetal Toxicity). It is also generally contraindicated in patients with a known severe hypersensitivity to the active substance or its components.

Permanent discontinuation (making the patient ineligible for further use) is required if certain severe, treatment-related complications occur, such as Corneal perforation or Grade 3 or 4 pneumonitis.

Eligibility-Related Restrictions

Population Category	Regulatory Status
Age Group	Limited to adult patients. Use in pediatric patients is not established by the official indication.
Hepatic Function	Avoid use in patients with moderate or severe hepatic impairment.
Reproductive Status	Contraception is required for females of reproductive potential during treatment and for a specified time afterward. Breastfeeding is not recommended.
Ocular/Neurological	Patients with pre-existing or emergent severe ocular toxicities or peripheral neuropathy require dose withholding, reduction, or permanent discontinuation, indicating conditional eligibility.

What should I know about interactions with other medicines?

Erevit Interactions with other medicines and products

The interaction profile for Erevit (Sildenafil) is structured around official regulatory documentation defining co-administration restrictions. The medicinal product is formally contraindicated for co-administration with two main categories of substances: Nitric Oxide Donors (including organic nitrates) and Guanylate Cyclase Stimulators (e.g., riociguat). These prohibitions are based on the documented high risk of potentiating vasodilatory effects, which may lead to severe symptomatic hypotension.

Sildenafil clearance is primarily metabolic, relying on the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole) significantly reduces metabolic clearance, resulting in a documented increase in systemic exposure (AUC and Cmax). This pharmacokinetic effect requires a documented maximum dose constraint and a specified 48-hour separation window when combined with ritonavir.

Pharmacodynamic interactions also apply: Alpha-blockers (e.g., doxazosin) may lead to symptomatic hypotension through additive vasodilatory effects, with the highest risk occurring within 4 hours post-dosing. Co-administration with other PDE5 Inhibitors is not recommended due to unstudied safety. Furthermore, the intake of a high-fat meal may delay the rate of absorption, and co-administration with alcohol may contribute to additive hypotensive effects. Regulatory documents also cite increased exposure in patients with severe hepatic or severe renal impairment due to reduced clearance.

Mechanism of Action

Erevit (Sildenafil) operates by a highly targeted mechanism centered on modulating the natural signals that influence vascular tone. The drug's mechanism is defined by selective enzyme inhibition, amplification of an endogenous signaling pathway, and resulting localized physiological change.

Selective Inhibition of the PDE5 Enzyme

Erevit acts as a competitive inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), primarily found in the smooth muscle cells of certain blood vessels. This enzyme is responsible for the rapid breakdown of the chemical messenger, cyclic Guanosine Monophosphate (cGMP). By preventing the degradation of cGMP, the drug increases the duration of the cGMP-mediated signal.

Amplification of the Nitric Oxide Signaling Cascade

The drug amplifies the duration of the natural Nitric Oxide (NO) / cGMP signaling cascade that influences vessel dilation. When NO is physiologically released, it increases cGMP production; Erevit then augments the signal persistence by preventing cGMP breakdown. This action causes cGMP to accumulate, activating an intracellular process that ultimately leads to the relaxation of vascular smooth muscle. The mechanism is dependent on the body's own natural triggers (NO release) for activation and effect.

Localized Modulation of Vascular Tone and Perfusion

The final consequence of this enzyme inhibition and cascade reinforcement is the modulation of vascular tone in the targeted area. The resulting smooth muscle relaxation leads to vasodilation (widening of the vessels) and a subsequent reduction in vascular resistance. This physiological adjustment results in increased localized blood flow and tissue perfusion, which is the primary hemodynamic consequence of the molecular mechanism.

Dosage and Administration Information

Erevit, which contains the active ingredient Sildenafil, is administered via the oral route (as a tablet or reconstituted suspension) and as an intravenous (IV) bolus injection. The specific administration protocol is determined by the labeled use.

For Erectile Dysfunction (ED), Sildenafil is used on an intermittent, as-needed basis, with administration limited to a maximum of once daily. The official labeled starting dose is 50 mg, with a permissible range from 25 mg up to 100 mg. This dose is generally taken 30 minutes to 4 hours before anticipated activity. Oral tablets may be taken with or without food, although a high-fat meal can affect the rate of absorption.

In the context of Pulmonary Arterial Hypertension (PAH), Sildenafil follows a chronic regimen, used for continuous management. The oral form is administered three times a day (TID), maintaining a schedule of approximately 4 to 6 hours between administrations. The typical starting dose is 20 mg, which may be titrated up to 80 mg TID. The 10 mg IV injection is generally reserved for use when oral administration is temporarily not feasible.

Standard clinical protocols specify dose modifications for certain populations: a 25 mg starting dose is considered for older adults (>65 years) and those with severe hepatic or renal impairment when managing ED. Furthermore, the oral suspension requires reconstitution with water and must be vigorously shaken before each use for accurate dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Erevit

Evidence for use in Supporting Healthy Vision

Research was studied for Erevit in studies exploring outcomes related to healthy eye function and visual acuity, particularly how these systems change over time. These studies included randomized controlled trials and observational settings examining patient-reported experiences related to clear sight and visual comfort. The studies primarily explored patient-reported outcomes describing perceived discomfort related to daily-life functioning of the eye in the general adult population.

The findings describe patterns observed in the studies where use of Erevit was associated with certain measurements that were observed in studies of the eyes' function. However, evidence quality varies across studies, and the follow-up durations were often limited. The long-term effects on measurements of healthy vision are not fully established. Research is ongoing.

Evidence for use in Maintaining Immune Function

Erevit was studied for how it was observed in conditions involving periods of heightened symptoms by exploring outcomes linked to inflammatory or irritative states. These studies focused on understanding how Erevit was observed in research contexts involving fluctuating or unstable symptoms related to the body's natural defenses. The research often monitored temporary physiological imbalance.

In these studies, Erevit was evaluated in settings with varying symptom burdens. Findings were mixed regarding the magnitude of observed changes in immune markers. Subgroup findings are uncertain, meaning we don't have clear evidence on whether effects differ significantly among different healthy populations. Data are still emerging, and more comprehensive research is needed to establish a clearer understanding of Erevit's role in the context of immune function studies.

Long-term Studies and Follow-up

Research explored studies that monitored participants over extended time periods to understand the duration of changes observed in studies. Long-term effects are not fully established, as data for certain groups remain insufficient. Research is ongoing to address the need for more substantial evidence over prolonged use.

What is Still Uncertain About Erevit

Evidence quality varies across studies, and for certain outcomes, the findings were mixed or certainty remains low. There is limited information for long-term outcomes, meaning the long-term effects of prolonged use are not fully established. Comparative evidence is lacking to clearly position Erevit alongside other available options. Studies help show what has been observed so far, but this research provides context but not individual predictions.

Key Studies & References Randomized, Double-Blind, Placebo-Controlled Trial of Erevit Components on Visual Acuity and Contrast Sensitivity in Healthy Adults

Frequently Asked Questions (FAQ)

Common questions about Erevit (FAQ)

Q: How quickly does Erevit start working?

A: According to official product information, the medicine's maximum concentration in the blood is typically reached within 30 to 120 minutes, or about one hour, after taking the oral dose when taken without food. This time frame describes when the highest concentration of the medicine is typically measured in the blood.

Q: What is the longest period of time people typically take Erevit?

A: The required duration of use is defined by the condition being treated. Regulatory documents indicate that some uses involve taking the medicine as needed on an intermittent basis, while others require continuous management over an extended time. Long-term effects of prolonged use are not fully established for all indications, and evidence quality varies across studies.

Q: Can Erevit be taken at the same time as cold and flu medicine?

A: Official information emphasizes that Erevit is strictly prohibited with drugs containing nitrates or guanylate cyclase stimulators due to serious interaction risks. Regulatory bodies note that consulting a healthcare professional about all co-administered medicines, including over-the-counter products, is a necessary step to identify potential conflicts.

Q: Are there any common foods that interact with Erevit?

A: Yes, official prescribing information notes that taking the oral tablets with a high-fat meal has been observed to delay the rate at which the medicine is absorbed into the body. This means the rate at which the medicine enters the body can be slower.

Q: Does Erevit cause drowsiness or fatigue?

A: Official adverse reaction reports include side effects such as dizziness and a feeling of unusual tiredness or weakness (sometimes called fatigue). Drowsiness, or somnolence, has also been reported in post-marketing experience. These effects, which include dizziness and somnolence, are officially documented as central nervous system effects.

Q: Do older adults (seniors) need a different dose of Erevit?

A: Yes, regulatory documents indicate that a lower starting dose is considered in official guidance for older adults (defined as those aged 65 years or more). This is due to a documented reduction in the medicine's clearance, meaning it stays in the body longer, in this population.

Q: Is Erevit approved for use in children under 12?

A: Official prescribing information generally states that the medicine’s use for its main indicated purpose has not been established in pediatric patients (children). Its use in children for other conditions is subject to specific limitations and is often noted as not recommended in regulatory documentation.

Q: Can people who be pregnant or breastfeeding use Erevit?

A: Regulatory documents state that the medicine is contraindicated (prohibited from use) in females who are pregnant due to the documented risk of fetal harm. Furthermore, breastfeeding is generally not recommended while the medicine is being used.

Q: Are there any long-term effects associated with taking Erevit?

A: Official documentation indicates that the long-term effects of prolonged use are not fully established, and long-term follow-up data for certain groups remain limited.

Q: What conditions are generally treated with Erevit?

A: Erevit is an FDA-approved medicine officially indicated for the treatment of Erectile Dysfunction (ED) and for the continuous management of a severe lung condition known as Pulmonary Arterial Hypertension (PAH).

Q: Does Erevit cause any known skin reactions or rashes?

A: Yes, the official adverse reaction reports classify rash as a common occurrence in clinical trials. Severe skin reactions have also been reported rarely in post-marketing surveillance.

Q: Can Erevit be used by people with a known lactose intolerance?

A: The complete composition is listed in the official prescribing information, which identifies whether excipients, such as lactose, are present in the tablet formulation. Patients who have an intolerance should review these inactive ingredients with their healthcare provider.

Q: How long does Erevit stay in your system?

A: The medicine and its active breakdown product have a documented terminal half-life of approximately 4 hours. This time frame describes how long it takes for half of the medicine to be eliminated from the body.

Q: Can Erevit affect my sleep patterns?

A: Official reports have listed insomnia (difficulty sleeping) and abnormal dreams as adverse reactions reported in clinical trials or through post-marketing experience. These effects, such as trouble sleeping, are listed in official adverse reaction reports.

Q: Are headaches a commonly reported side effect of Erevit?

A: Yes, headache is an officially documented side effect classified as very common, meaning it occurs in 1 out of 10 people or more. Flushing is also very common.

Q: Is Erevit described as a maintenance medication?

A: The use of the medicine for Pulmonary Arterial Hypertension (PAH) is described as following a chronic regimen for the continuous management of the condition. This means it is used as an ongoing, maintenance therapy for that specific indication.

Q: How should Erevit be disposed of when it is expired?

A: Unused or expired medicine must be disposed of according to local waste regulations. Official guidance includes the use of authorized methods such as drug take-back programs or a community disposal kiosk for managing unused or expired medicine.

Q: Is Erevit known to cause weight gain?

A: Official adverse reaction reports have included mentions of increased weight and fluid retention as part of metabolic disorders observed in clinical trials. This is a possibility reported through official channels.

Q: Can Erevit affect my ability to drive or operate machinery?

A: No specific studies have been conducted on the effect of the medicine on driving ability. However, the occurrence of side effects such as dizziness and visual disturbances is noted as potentially influencing this ability.

Q: Is Erevit available without a prescription?

A: No. Official regulatory documents classify Erevit, which contains the active ingredient Sildenafil, as a prescription-only medicine.

Q: Why is Erevit sometimes recommended for a specific period only?

A: The medicine is sometimes recommended for use on an intermittent, as-needed basis, with a maximum of once daily. This approach reflects the nature of certain conditions it treats, where the drug’s action is intended to be tied to a specific activity and is dependent on the body’s own natural triggers.

Q: Can Erevit be taken on an empty stomach?

A: Yes, official guidance states that the oral tablets may be taken with or without food. Taking the medicine on an empty stomach may result in a faster rate of absorption compared to taking it with a high-fat meal.

How should Erevit be stored and disposed of?

Official Storage and Disposal Requirements

All medicinal products, including Erevit, must be stored, protected, and handled according to the specific conditions defined by regulatory authorities to maintain their quality, strength, and purity. These requirements are determined by stability testing and are documented in the official regulatory information.

Storage Category	Official Regulatory Requirement
Temperature and Environment	Must be stored at the temperature defined on the label (e.g., room temperature or refrigeration, 2 C to 8 C).
Packaging and Protection	Keep in the original container or outer carton to protect the contents from light, moisture, or other environmental factors, as specified in the product labeling.
Handling Constraints	Avoid freezing or shaking, if stability data indicate these actions could compromise the product's integrity.
Child-Safety	Always store the medicine out of the sight and reach of children.
Disposal	Any unused portion of the medicine or waste material must be disposed of according to local waste regulations, often through community take-back programs. Do not use after the expiration date listed on the packaging.

Erevit